- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05191186
Documentation of Efficacy of Intralymphatic Allergen Immunotherapy (ILITNU)
Documentation of Efficacy of Intralymphatic Allergen Immunotherapy in a Phase III Randomized, Parallel Group Placebo Controlled Double Blind Multisite Field Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A double-blind, parallel group, placebo controlled multi-site trial of the clinical efficacy of 3 intralymphatic injections with a low dose of grass pollen extract into inguinal lymph nodes in grass pollen allergic subjects.
Primary endpoint is the difference in combined symptom and medication score during grass pollen seasons following treatment compared with patients receiving placebo.
Injections are giving ultrasound-guided with at least 4 weeks intervals.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- moderate-severe grass pollen allergic rhinoconjunctivitis
- positive skin prick test for grass pollen extract
Exclusion Criteria:
- significant mugwort allergy
- previous AIT for grass pollen allergy
- uncontrolled non-allergic upper airways disease
- uncontrolled asthma
- planned depot steroid injections during season
- uncontrolled autoimmune diseases
- active malignancies
- uncontrolled other severe condition, including psychiatric diseases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: grass pollen extract treatment
participants receive 3 injections with Alutard phleum pratense, ALK, grass pollen extract
|
injection in lymph node
Other Names:
|
PLACEBO_COMPARATOR: Placebo
Participants receive 3 injections with saline (NaCl 0.9%)
|
injection in lymph node
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Combined symptom and medication score, cSMS
Time Frame: 2 years
|
daily combined symptom and medication scores during grass pollen seasons in 2022 and 2023 as compared to placebo. cSMS is a combined score of a symptom score, 0-3, where 0 indicates no symptoms and 3 indicates severe symptoms and meddication score 0-3 according to the us of reliever medication: 0: no medication, 1: antihistamine use, 2: local steroid use, 3: systemic steroid use. This results in a score ranging from 0 (no symptoms, no need for medications) to 6 (severe symptoms and need for maximum reliever medication |
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
side-effects
Time Frame: 3 months
|
occurence of side-effects as compared to placebo
|
3 months
|
correlation of CSMS to pollen count
Time Frame: 2 years
|
correlate cSMS to daily pollen counts
|
2 years
|
combined symptom and medication score, cSMS
Time Frame: 2 years
|
change in the combined symptom and medication score from baseline
|
2 years
|
Rhinitis related quality of life, RQLQ
Time Frame: 2 years
|
changes on rhinitis related quality of life
|
2 years
|
Airwave oscillometry system(AOS), asthma
Time Frame: 2 years
|
Influence of ILIT on resistance in the lower airways measured by AOS
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Johannes M Schmid, MD PhD, Aarhus University Hospital/Aarhus University
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Eye Diseases
- Otorhinolaryngologic Diseases
- Respiratory Hypersensitivity
- Hypersensitivity
- Nose Diseases
- Conjunctival Diseases
- Rhinitis
- Rhinitis, Allergic
- Conjunctivitis
- Conjunctivitis, Allergic
Other Study ID Numbers
- 2020-001060-28
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Rhinitis Due to Grass Pollen
-
University of ZurichAlleCureCompletedRhinoconjunctivitis Due to Grass Pollen AllergySwitzerland
-
Medical University of ViennaAstraZenecaCompletedAllergic Rhinitis Due to Grass Pollen | Allergic AsthmaAustria
-
Lars Olaf CardellRecruitingAllergic Rhinitis Due to Grass PollenSweden
-
AlyatecCompletedAllergic Rhinitis Due to Grass PollenFrance
-
Lars Olaf CardellCompletedAllergic Rhinitis Due to Grass PollenSweden
-
Medical University of LublinCompletedAllergic Rhinitis Due to Grass PollenPoland
-
AOBiome LLCIntegrium; Orange County Research CenterCompletedAllergic Rhinitis Due to Grass Pollen | Allergic Rhinitis | Healthy VolunteersUnited States, Canada
-
PuressentielInstitut National de la Santé Et de la Recherche Médicale, FranceNot yet recruitingAllergic Rhinitis Due to Grass Pollen | Allergic Inflammation
-
Hopital FochCompletedAllergic Rhinitis Due to Grass PollenFrance
-
University of ZurichUniversity of AarhusActive, not recruitingAllergic Rhinitis Due to Grass Pollen | Allergic Rhinitis | Rhinitis, Allergic, Seasonal | Allergic Asthma | Rhinitis; Allergic, With AsthmaSwitzerland
Clinical Trials on Grass pollen extract - Alutard Phleum pratense, ALK
-
Bispebjerg HospitalALK-Abelló A/SCompletedAllergic Rhinitis Due to Grass PollensDenmark
-
AbbottCompletedSeasonal Allergic RhinitisRussian Federation
-
Aarhus University HospitalUniversity of Aarhus; ALK-Abelló A/S; Lundbeck FoundationCompleted
-
ALK-Abelló A/SCompletedConjunctivitis | Rhinitis Allergic
-
Karolinska InstitutetCompleted
-
Imperial College LondonALK-Abelló A/SUnknownRhinitis, Allergic, SeasonalUnited Kingdom
-
Karolinska InstitutetKarolinska University Hospital; Skane University Hospital; Sodra Alvsborgs HospitalCompletedRhinitis, AllergicSweden
-
Imperial College LondonALK-Abelló A/SCompletedRhinitis, Allergic, SeasonalUnited Kingdom
-
Roxall Medicina España S.ACompletedAllergic RhinoconjunctivitisSpain
-
Rigshospitalet, DenmarkTRYG FoundationCompleted